GlassScriptPhysician profile
Andrew C Friedman
NPI 1598737223
$7,025.92
in general payments reported to CMS, 2019-2025
31 companies · $18.58 in 2025
The $18.58 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,790 · 2020: $1,337 · 2021: $1,455 · 2022: $1,159 · 2023: $1,198 · 2024: $70.03 · 2025: $18.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,165.45 | 2019-2023 | Repatha |
| Pfizer INC. | $857.40 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $800.64 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $478.80 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $382.13 | 2021-2023 | Verquvo |
| Boston Scientific Corporation | $365.84 | 2019-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $279.88 | 2020-2023 | Camzyos, Eliquis |
| Novo Nordisk INC | $268.49 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.91 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $235.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $235.40 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $230.08 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $209.28 | 2019-2021 | |
| Abbott Laboratories | $196.83 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.78 | 2019-2023 | Lifevest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $138.91 | 2022-2023 | Arcalyst |
| Portola Pharmaceuticals, LLC | $114.00 | 2020 | |
| Edwards Lifesciences Corporation | $107.13 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $81.18 | 2020-2022 | |
| Akcea Therapeutics, INC. | $78.59 | 2019-2020 | |
| Astellas Pharma US INC | $73.06 | 2019-2021 | |
| Esperion Therapeutics, INC. | $54.37 | 2021-2023 | Nexletol |
| Inspire Medical Systems, INC. | $54.14 | 2023-2024 | Inspire |
| Daiichi Sankyo INC. | $46.71 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $38.08 | 2022-2023 | Amvuttra |
| Althera Pharmaceuticals LLC | $37.59 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $29.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.03 | 2020-2021 | |
| Altathera Pharmaceuticals LLC | $16.48 | 2023 | Sotalol Hydrochloride |
| Genzyme Corporation | $16.05 | 2021 | |
| Gilead Sciences, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.